Table 4.

Recurrence free survival and overall survival correlation with PD-L1 and stromal tumor infiltrating lymphocytes in patients treated with trastuzumab and non-trastuzumab based chemotherapy

A. Trastuzumab based chemotherapy
	Recurrence Free Survival				Overall Survival
	Overall	Recurrence	No recurrence	p-value	Overall	Death	No death	p-value
	(n=110)	(n=16)	(n=94)		(n=115)	(n=13)	(n=102)
TIL-Str	25 (0-85)	20 (8-45)	25 (0-85)	0.576	25 (0-85)	14 (3-85)	25 (0-80)	0.102
28-8 in tumor	1.7 (0-85)	0.7 (0-11.7)	1.7 (0-85)	0.336	1.7 (0-85)	3.8 (0-66.7)	1.6 (0-85)	0.747
28-8 in TILs	5 (0-91.7)	0.6 (0-26.7)	8.1 (0-91.7)	0.034	5 (0-91.7)	1.9 (0-60)	5.6 (0-91.7)	0.305
22C3 in tumor	0 (0-73.3)	0 (0-0.8)	0.6 (0-73.3)	0.185	0 (0-73.3)	0 (0-51.7)	0 (0-73.3)	0.534
22C3 in TILs	2.5 (0-66.7)	1.3 (0-26.7)	2.5 (0-66.7)	0.606	2.5 (0-66.7)	0 (0-61.7)	2.5 (0-66.7)	0.407
B. Non-Trastuzumab based chemotherapy
	Recurrence Free Survival				Overall Survival
	Overall	Recurrence	No recurrence	p-value	Overall	Death	No death	p-value
	(n=72)	(n=14)	(n=58)		(n=76)	(n=7)	(n=69)
TIL-Str	22 (0-75)	13 (0-50)	25 (5-75)	0.064	22 (0-75)	3 (5-10)	20 (0-75)	0.009
28-8 in tumor	0.8 (0-15)	0 (0-2.7)	0.8 (0-15)	0.083	0.2 (0-15)	0.8 (0-8.3)	0 (0-15)	0.741
28-8 in TILs	0.9 (0-35)	0 (0-11.7)	1.5 (0-35)	0.185	0.8 (0-35)	0.4 (0-1.1)	0.8 (0-35)	0.728
22C3 in tumor	0 (0-10)	0 (0-0.4)	0 (0-10)	0.688	0 (0-13.8)	0 (0-0.1)	0 (0-13.8)	0.39
22C3 in TILs	0 (0-35)	0 (0-18.8)	0 (0-35)	0.925	0 (0-35)	0 (0-0)	0 (0-35)	0.212